Zacks Research Weighs in on GSK’s Q1 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Equities research analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for shares of GSK in a research note issued on Wednesday, December 11th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $1.12 per share for the quarter, down from their prior estimate of $1.14. The consensus estimate for GSK’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK’s Q2 2026 earnings at $1.12 EPS and Q3 2026 earnings at $1.52 EPS.

A number of other equities analysts have also commented on GSK. Barclays upgraded shares of GSK to a “hold” rating in a research report on Tuesday, August 27th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat, GSK has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Up 1.9 %

GSK stock opened at $34.23 on Monday. The stock has a 50-day simple moving average of $36.00 and a two-hundred day simple moving average of $39.06. GSK has a twelve month low of $32.83 and a twelve month high of $45.92. The firm has a market capitalization of $70.94 billion, a PE ratio of 22.23, a PEG ratio of 1.54 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be issued a $0.3928 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.59%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio is presently 98.70%.

Insider Activity

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Institutional Investors Weigh In On GSK

A number of hedge funds and other institutional investors have recently modified their holdings of GSK. FMR LLC increased its stake in GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after purchasing an additional 2,224,345 shares during the period. Fisher Asset Management LLC increased its stake in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after buying an additional 870,449 shares during the period. Primecap Management Co. CA raised its holdings in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the last quarter. Provident Trust Co. boosted its position in GSK by 1.7% during the 3rd quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC grew its holdings in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after acquiring an additional 833,080 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.